Status:
COMPLETED
Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment
Lead Sponsor:
AstraZeneca
Conditions:
Colorectal Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study is for patients with metastatic adenocarcinoma arising from the colon or rectum who have received treatment(s) for metastatic disease with subsequent disease progression. Patients who are i...
Eligibility Criteria
Inclusion
- Radiographic evidence of metastatic, progressive disease following standard therapies.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
Exclusion
- Known brain metastases or uncontrolled pleural effusions.
- History of chronic inflammatory or autoimmune disease.
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT00313794
Start Date
May 1 2006
End Date
June 1 2008
Last Update
June 7 2012
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Bessemer, Alabama, United States, 35022
2
Research Site
Birmingham, Alabama, United States, 35205
3
Research Site
Birmingham, Alabama, United States, 35209
4
Research Site
Birmingham, Alabama, United States, 35211